Pancreatic Adenocarcinoma Non Resectable clinical trials

Explore recruiting pancreatic adenocarcinoma non resectable clinical trials.

Recruiting pancreatic adenocarcinoma non resectable studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Adenocarcinoma Non Resectable trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

RR001 in Combination with Chemotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCR-Modified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients with Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes

Germany, Denmark, Netherlands, Sweden

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

France, Spain, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advanced Solid Tumors

Spain, France, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

C5721001 - Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Germany, Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Pancreatic Adenocarcinoma Non Resectable trials by city

Pancreatic Adenocarcinoma Non Resectable in Toronto Pancreatic Adenocarcinoma Non Resectable in Vancouver Pancreatic Adenocarcinoma Non Resectable in Montreal Pancreatic Adenocarcinoma Non Resectable in Calgary Pancreatic Adenocarcinoma Non Resectable in Edmonton Pancreatic Adenocarcinoma Non Resectable in Ottawa Pancreatic Adenocarcinoma Non Resectable in Winnipeg Pancreatic Adenocarcinoma Non Resectable in Quebec City Pancreatic Adenocarcinoma Non Resectable in Hamilton Pancreatic Adenocarcinoma Non Resectable in Kitchener Pancreatic Adenocarcinoma Non Resectable in London Pancreatic Adenocarcinoma Non Resectable in Halifax Pancreatic Adenocarcinoma Non Resectable in New York Pancreatic Adenocarcinoma Non Resectable in Los Angeles Pancreatic Adenocarcinoma Non Resectable in Chicago Pancreatic Adenocarcinoma Non Resectable in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease